The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham is a clinical research site located in Birmingham, Alabama, United States 35294.
Crixeo Health Trust Score: 72/100 (FAIR). This profile has not yet been claimed by the site owner.
The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham has participated in 5 clinical trials with 1 currently active.
Therapeutic areas: Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma.
Sponsors: Seagen, a wholly owned subsidiary of Pfizer, Eisai Inc., Naurex, Inc, an affiliate of Allergan plc.
Trust Score: 72/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.
The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham has a Crixeo Trust Score of 72/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham has 5 clinical trials on record, with 1 currently active. Their work covers Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma.
Yes — The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.